Month: June 2022

Tegningsperioden for udbud af afdelingen Indeks High Yield Obligationer i Investeringsforeningen PFA Invest er afsluttet den 9. juni 2022 kl. 16.00.Resultatet blev følgende:PFA Invest afdeling ISIN-kode Antal investorer Antal andele stk. Formue i kr.Indeks High Yield Obligationer DK0061804424 1 9.940.358 1.000.000.014,80PFA Pension, forsikringsaktieselskab har tegnet for 1.000.000.014,80 kr. kr. i afdelingen og indgår som investor i ovenstående resultat af tegningen. Andele i afdelingerne var udbudt til tegningskurs 100,60. Andele i afdelingen forventes optaget til handel på NASDAQ Copenhagen A/S den 14. juni 2022. Med venlig hilsenPFA Asset Management A/S Rasmus BessingDirektør          

NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of Acute Myeloid Leukemia (AML) cell lines. NUC-7738 has already shown promise as monotherapy in patients with solid tumors in a Phase 1/2 study (NuTide:701) and will also be combined with a PD-1 checkpoint inhibitor. The data at EHA 2022 show that NUC-7738 can suppress the expansion and survival of AML cells by reducing β-catenin signaling,...

WATERTOWN, Mass., June 10, 2022 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that a late-breaking abstract highlighting 12-month data from the Phase 1 DAVIO clinical trial evaluating EYP-1901 for the treatment of wet age-related macular degeneration (wet AMD) has been selected for presentation at the American Society of Retinal Specialists (ASRS) 2022 Annual Meeting to be held in New York City from July 13 – 16, 2022. Presentation details are as follows: Presentation Title: 12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert® Insert for nAMD: The DAVIO TrialSession Title: Wet AMD 2 SymposiumDate and Time: Friday, July 15, 2022 at 8:00...

Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that the company will present clinical trial design details for two of its wholly-owned investigative therapies, NX-2127 and NX-5948, each currently in Phase 1 development, at the EHA2022 Hybrid Congress. The meeting is being held from June 9-12, 2022 in Vienna, Austria and virtually. Poster and presentation details are included below: Title: A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies...

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due to adverse events (AEs); oral, once-daily administration provided expected CNS exposure Data support further development of CY6463 in CNS diseases with mitochondrial dysfunction CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data in its signal-seeking clinical study of CY6463, for the potential treatment of Mitochondrial Encephalomyopathy, Lactic...

— NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA’s Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 — — New Phase 2 Study Announced to Evaluate Nirogacestat in Patients with Ovarian Granulosa Cell Tumors — — Eight Clinical Collaborations Evaluating Nirogacestat as a Cornerstone of BCMA Combination Therapy Ongoing; Nirogacestat in Combination with Low Dose of GSK’s BLENREP Being Evaluated in Phase 2 Trial and Advanced into Additional Sub-Studies with Standard of Care Agents — — Mirdametinib Being Evaluated in Monotherapy and Combination Studies in Rare Oncology Indications and Biomarker-Defined Solid Tumors — — BGB-3245 Monotherapy to Advance into Cohort Expansion Studies — — Well Capitalized to Execute Across...

The five-round series has a US $250,000 prize fund at stake and more flexible regulations for pro driversLe Mans Virtual Series 2022/2023 Calendar Photo 1MIAMI, June 10, 2022 (GLOBE NEWSWIRE) — Le Mans Virtual Series, a joint venture between Motorsport Games Inc. (NASDAQ: MSGM) and the Automobile Club de l’Ouest (ACO), returns this September with more of the elite, endurance esports competition, which has attracted world motor racing champions, captured global attention and received plaudits from teams, drivers and fans alike. The announcement was made today at the official ACO annual press conference ahead of the 90th running of the 24 Hours of Le Mans. Last year’s successful Le Mans Virtual Series culminated in a thrilling 24 Hours of Le Mans Virtual in January 2022. Multiple major motorsport manufacturers and their drivers...

BARDA has ordered 500,000 doses of liquid-frozen JYNNEOS® to be manufactured from existing bulk vaccine for delivery in 2022 Order brings the total U.S. inventory of liquid-frozen JYNNEOS to nearly 2 million doses Company upgrades financial guidance for 2022COPENHAGEN, Denmark, June 10, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 500,000 doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox, for delivery in 2022. With the previous order from BARDA for 1.4 million doses of liquid-frozen JYNNEOS, awarded in 2020, this order will bring...